Novartis agreed to pay $2 billion upfront to acquire Pikavation Therapeutics to gain pan-mutant selective PI3Kα inhibitor programs led by SNV4818, a Phase I/II oral candidate in breast cancer and other advanced solid tumors. The deal also includes up to $1 billion in milestones as Novartis looks to improve tolerability versus earlier PI3Kα approaches by selectively targeting mutant PI3Kα while sparing wild-type enzyme.

Why It Matters To Oncology

• Mutated PI3Kα is a well-established driver in HR+/HER2− breast cancer, but tolerability has limited how aggressively the pathway can be inhibited and combined with other agents.

• SNV4818 is designed to hit mutant PI3Kα while sparing wild-type PI3Kα in healthy cells, aiming to reduce side effects and enable more consistent dosing.

• Novartis says that profile could make PI3Kα inhibition easier to combine with hormonal therapy and other treatments (e.g., CDK inhibitors) earlier in the treatment course.

The Financials

• $2B upfront to acquire Pikavation Therapeutics (a Synnovation Therapeutics subsidiary).

• Up to $1B in development, regulatory, and commercial milestones.

• Transaction expected to close in 1H 2026.

What They're Saying

• Novartis development president Shreeram Aradhye: “While mutated PI3Kα is a well‑established driver in HR+/HER2‑ breast cancer, there remains a challenge in achieving effective pathway inhibition with a tolerable therapeutic profile.”

• Aradhye on the strategy: “SNV4818 applies new mutant‑selective chemistry to more precisely target tumour biology while sparing normal cells… [with] potential to translate proven biology into improved tolerability and more durable benefit.”

What's Next

• Clinical readouts from the ongoing Phase I/II study in breast cancer and other advanced solid tumors will determine whether mutant selectivity translates into a wider therapeutic window.

• Competitive positioning will be watched closely against Novartis’ own approved PI3Kα inhibitor Piqray (alpelisib) and Roche’s Itovebi (inavolisib) in HR+/HER2−, PIK3CA-mutant breast cancer.

• Dealwatch: the acquisition echoes Eli Lilly’s agreement (announced ~12 months ago) to buy Scorpion’s mutant-selective PI3Kα program (STX-478) for up to $2.5B, underscoring sustained pharma appetite for next-gen PI3Kα assets.